NDAOralTablet
Approved
Nov 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
VFEND (voriconazole) by Pfizer is cytochrome p450 3a4 inhibitors [moa]. First approved in 2003.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VFEND (voriconazole) is a small-molecule azole antifungal that inhibits fungal cytochrome P450 3A4, disrupting ergosterol synthesis in fungal cell membranes. It is indicated for treatment of invasive aspergillosis and other serious fungal infections in immunocompromised patients. The oral tablet formulation provides convenient dosing for both acute and maintenance therapy.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and shift toward lifecycle management or brand defense roles.
Mechanism of Action
Cytochrome P450 3A4 Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study on the Drug Interaction Between Buagafuran and Voriconazole
Started Apr 2026
18 enrolled
Drug Drug Interaction (DDI)
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
Started Feb 2026
60 enrolled
Invasive Mould Infection
A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
Started Aug 2024
32 enrolled
Healthy Volunteers
A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets
Started Dec 2019
16 enrolled
AnesthesiaSedation
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Started Jan 2019
22 enrolled
Invasive Pulmonary Aspergillosis
Worked on VFEND at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.